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Introduction
The Australian Federal government has recently com-
pleted a two-year review into the safety, effectiveness
and cost-effectiveness of positron emission tomography
(PET). The review process, which included a thorough
critique of the current literature as well as consultation
with experts in the field, has led to extended public
funding of PET within Australia. A further positive
outcome is a freely available evidence-base for the
clinical use of PET that provides a valuable resource for
specialists with an interest in cancer imaging throughout
the world (www.health.gov.au/haf/pet). This article
summarises the review findings with respect to the level
of service provision, suitable imaging technologies and
clinical indications than can be justified on the basis of
current evidence.
Service provision and technology
The review has recommended funding of seven PET
centres across Australia, approximately equivalent to
one PET scanner per three million population. The
centres were to be sited at facilities with comprehen-
sive cancer care (major sub-specialty surgery, medical
oncology, radiation oncology) and neuroscience (neuro-
surgery/neurology) services, located within a major
teaching hospital. The review considered the performance
of gamma camera based PET systems and partial ring
dedicated PET systems to be inadequate, with funding
to be limited to services performed on dedicated full-
ring PET systems using as a detector material, bismuth
germinate (BGO), sodium iodide (NaI) or newer crystal
technologies. Although BGO systems were thought to
have an advantage over NaI for research applications,
the performance differences were judged to be small
for clinical studies using fluorodeoxyglucose (FDG) that
were to be funded following the review.
Clinical indications
The available evidence for clinical effectiveness and
cost-effectiveness was believed insufficient to allow
unrestricted funding. Therefore funding (on a fee-for-
service basis) was to be restricted to a limited range of
specific clinical indications, including seven applications
within oncology for lung cancer, malignant melanoma,
cerebral glioma and recurrent colorectal cancer. All
funded cases were to be included in an on-going data
collection and analysis process to confirm clinical impact
and cost-effectiveness so that long-term decisions about
the role of PET in Australia could be made.
For lung cancer, PET was felt to have high accuracy
and to provide sufficient clinical impact to justify its
use for characterisation of solitary pulmonary nodules,
but funding was recommended only if the nodule
were unsuitable for fine-needle aspiration or if a prior
attempt at pathological diagnosis had failed. Similarly,
the accuracy and therapeutic impact of PET in staging
non-small cell cancer was found to be sufficiently high
as to allow funding prior to surgery or radiotherapy with
curative intent. There was insufficient data to support
funding of PET for re-staging or therapy monitoring.
For malignant melanoma, PET was judged to be more
accurate than conventional imaging in the detection
of metastatic sites but this improved accuracy was
only likely to have therapeutic impact when PET
was performed prior to resection of apparently limited
metastatic disease.
The role of PET in cerebral glioma was considered to
need confirmation by further long-term studies. However,
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interim funding was allowed for distinction of radiation
necrosis from recurrence on the basis that current
evidence suggests greater accuracy for PET over MRI.
Interestingly, there was insufficient evidence to conclude
that PET was superior to thallium single photon emission
tomography (SPET) in this clinical situation. Funding
was also approved for PET grading of glioma on grounds
of greater accuracy than thallium SPET and the potential
to guide biopsy to the most active tumour region.
For recurrent colorectal cancer, the evidence supported
the use of PET in evaluating residual lesions after
definitive therapy on account of the ability for PET to
distinguish recurrence from fibrosis more reliably than
CT. PET was also approved prior to planned resection
of hepatic or pulmonary metastases due to the greater
sensitivity of PET for detection of extra-hepatic tumour
sites. Interestingly, the evidence did not demonstrate the
accuracy for PET in diagnosis of intra-hepatic disease to
be beyond existing modalities. The review also did not
recommend funding for investigation of a raised serum
carcinoembyonic antigen (CEA) level.
In addition, the review recommended a later evaluation
of PET in lymphoma, head and neck cancer, gynaeco-
logical malignancy, sarcoma and upper gastrointestinal
malignancy. Subsequently, interim funding has been
approved for specific applications in these tumours on a
similar basis to the indications outlined above.
Discussion
Increasingly, governments and other health purchasers
require an adequate evidence-base prior to agreeing to
fund new medical interventions. It therefore behoves
imaging specialists, and possibly equipment manufac-
turers, to conduct the research necessary to provide
such evidence. However, the Australian PET review has
raised important issues as to what an appropriate level
of evidence should be for diagnostic imaging tests, as
well as ethical concerns about how such information
should be obtained. For instance, is it reasonable to ask
for evidence of how a diagnostic imaging test impacts
on ultimate outcomes, such as survival, when it is the
treatment rather than the diagnostic methodology that
primarily determines ultimate outcome? Is it ethical
within a study to determine the effect of an imaging
modality on ultimate outcomes, to randomise a patient
towards investigation with previous methods when the
new modality has already been shown to be more
accurate? The danger of seeking an inappropriate level of
evidence is the possibility of denying patients access to
technology from which they would otherwise benefit. On
the other hand, for those PET indications that have been
approved by the Australian review, it is possible to make
recommendations to our clinical colleagues and patients
with a high degree of confidence.
